RSV drug study for kids ends early – what we know

NCT ID NCT06102174

First seen Jan 07, 2026 · Last updated May 07, 2026 · Updated 17 times

Summary

This study looked at the safety and amount of a new medicine called sisunatovir in the blood of infants and children up to 5 years old with RSV lung infections. About 10 children took part, receiving either the drug or a placebo. The study was stopped early, but the results will help decide the right dose for future studies in children.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Kaiser Permanente

    Los Angeles, California, 90027, United States

  • Kaiser Permanente Los Angeles Medical center

    Los Angeles, California, 90027, United States

  • Kojunkai Daido Hospital

    Nagoya, Aichi-ken, 457-8511, Japan

  • Monti Clinical Research Centre

    Mdantsane, Eastern Cape, 5219, South Africa

  • Nintenkai Kagoshima Children's Hospital

    Hioki, Kagoshima-ken, 899-2503, Japan

  • Osaka City General Hospital

    Osaka, 534-0021, Japan

  • University of Witwatersrand (WITS) - Vaccines and Infectious Diseases Analytics (VIDA)

    Johannesburg, Gauteng, 2013, South Africa

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Yamanashi Prefectural Central Hospital

    Kofu, Yamanashi, 400-8506, Japan

Conditions

Explore the condition pages connected to this study.